The activated receptors cause changes in the expression of specific genes, which can stimulate cell growth. The estrogen-lowering effects of Arimidex and other hormone treatments taken during breast cancer treatment can potentially cause hair thinning in women. However, this is not a known side effect for male steroid users who use Arimidex. A much more significant concern is the side effects of many anabolic steroids of hair loss or male pattern baldness. There have even been studies comparing the effects of Arimidex and Letrozole (on women with breast cancer). One study found that Letrozole suppresses estrogen in the breast and circulating estrogen levels more so https://solutions.dustin.nl/blog/understanding-steroids-uses-risks-and-implications/ than Arimidex5.
The length of this treatment along with side effects, such as menopausal symptoms, can make it tough to complete treatment. Talk with your health care team about ways to ease these and other side effects. However, some premenopausal women may take an aromatase inhibitorwhen combined with ovarian suppression, which shuts down the ovaries.
Also, we must keep this in mind that basic vitamins and minerals like Vitamin D, zinc and magnesium which supports higher testosterone levels should be there in the estrogen blocker that we are buying. The men had standard blood tests done to check their hormone levels, then underwent a series of tests of cognitive ability, including tests for memory, visual reasoning, and overall mental state. It was seen that men with higher testosterone ticked all the above-mentioned boxes as compared to the ones with the lower levels. Several studies have also concluded that the inclusion of fiber-rich vegetables and fruits in diet results in a lower level of estrogen (17). This was shown amongst vegetarian postmenopausal female and non-vegetarian postmenopausal women.
At 3 months, 40% of patients who started treatment for mCSPC with APA + ADT had undetectable PSA, versus 29% who started treatment with ENZ + ADT, 23% with AAP + ADT, and 12% with CAB/ADT (Fig. 4). By 12 months, 61% of patients in the APA + ADT group had undetectable PSA versus 59% in the ENZ + ADT group, 54% in the AAP + ADT group, and 35% in the CAB/ADT group. Similar results were observed when CAB and ADT alone were assessed separately (Fig. S1). PSA90 was reached at 3 months by 52% of patients who started treatment for mCSPC with APA + ADT, versus 48% who started treatment with ENZ + ADT, 45% with AAP + ADT, and 33% with CAB/ADT (Fig. 4). By 12 months, 69% of patients in the APA + ADT group had reached PSA90 versus 62% in the ENZ + ADT group, 58% in the AAP + ADT group, and 52% in the CAB/ADT group.
A study in The Journal of Clinical Endocrinology & Metabolism found that maintaining estradiol levels between 20–30 pg/mL supports better metabolic and bone health in men on TRT, suggesting that complete estrogen suppression is undesirable. And lastly, always consult with a licensed physician, preferably one specializing in hormone replacement therapy, before taking a prescription estrogen blocker. The potential side effects of natural estrogen blockers are comparatively mild to those of pharmaceutical aromatase inhibitors. Similar to natural testosterone boosters, like Transparent Labs Vitality, several natural estrogen blockers can help balance the ratio of androgenic to estrogenic hormone levels in the body without totally shutting down the endocrine system.
